Global X S&P Biotech ETF (CURE) Review & Analysis

MER · Top 50%AUM · #343 of 5081Y Return · Top 10%3Y Return · Top 10%5Y Return · #126 of 225
What's new this monthData to 30 September 2026
  • +0.2% in September (total return), ahead of the median international shares ETF at +0.0%.
  • The unit price closed the month at $77.55, 5% below its 12-month high (range $46.01 to $81.49).

About CURE

CURE is an international shares ETF from Global X, listed on the ASX since November 2018. With $50m under management it is number 169 of 254 international shares ETFs by size. The management fee is 0.45% a year, about $45 on every $10,000 invested, cheaper than the typical international shares ETF at 0.55%.

Its largest holdings are Moderna Inc, Twist Bioscience Corp and Natera Inc, and the top 10 make up 18% of the fund. By sector it leans towards health care (100%).

Over five years it has returned +5.2% a year including distributions, against +8.8% for the median international shares ETF. With its focus on healthcare, it is the kind of fund many investors use as a smaller satellite holding alongside a diversified core.

CURE distributions and dividend dates

CURE pays distributions yearly, usually going ex-distribution in June, with payment about 15 days after the ex-date. (Pattern estimated from recent payments.)

The latest distribution was $0.024 per unit (0% franked), ex-distribution on 30 June 2022 and paid on 15 July 2022. To receive it you need to own CURE before the ex-date.

Its distribution yield over the past 12 months is about 0.0%. Distributions vary and past payments are not a guide to future ones.

From ASX announcements, updated nightly. See every ETF in the dividend calendar.

Compare CURE with

CURE price by TradingView

Stock CodeCURE
Fund ManagerGlobal X
Asset ClassInternational shares
AUM$50m
MER (%)0.45%
Net flows (Sep)$0.0m
Last Price$77.55
52-Week Range$46.01 – $81.49
Bid/Ask Spread0.34%
Listing Date12/11/2018
ExchangeASX
IndexNot yet in our data. See the PDS
Issuer websiteGlobal X ↗

Performance (% return)

0%33%66%99%1M0.2%1Y50.9%3Y98.5%5Y28.8%
1 month+0.2%
1 year+50.9%
3 years p.a.+25.7%
5 years p.a.+5.2%

$10,000 invested…

1 year ago$15,0883 years ago$19,8545 years ago$12,880

Value at 30 September 2026 with distributions reinvested, before tax and brokerage.

Total returns including distributions, to 30 September 2026. 1M, 1Y, 3Y and 5Y bars are cumulative.

CURE at a glance: strengths and things to watch

👍 Strengths

  • In an uptrend. Its price has been trending up since 13 November (as at 14 November).

⚠️ Things to watch

  • Small fund. With $50m under management, it is more at risk of being closed or merged than larger funds, and trading can be thinner.
  • Behind its peers. +5.2% a year over 5 years, against +8.8% for the median international shares ETF.

Worked out from CURE's fees, size, flows, returns and trend against the 257 international shares ETFs in Australia, to 30 September 2026. General information, not a recommendation.

Joshua StegaetfadviserTrend check
Uptrend since 13 Nov 2026

CURE is in an uptrend. Here's why that matters.

CURE's price is above its 20-day average and its 10, 20, 50 and 200-day averages are stacked upward. The trend is on investors' side.

Why it matters: Uptrends are when satellite ETFs tend to do their best work. The key is knowing when the trend breaks, so gains aren't handed back.

At ETF Adviser the core of a portfolio stays invested through every stage, and satellite ETFs are only bought in an uptrend. Members get a weekly update on which ETFs are breaking out of a base and which trends have broken.

Nov 25Feb 26May 26Aug 26Nov 26
UptrendBaseDowntrend

CURE weekly price, past 12 months, shaded by trend stage. Stage as at 14 November 2026, updated weekly. A technical label, not a recommendation.

Investment Focus

Exposure Regions

Global

Themes & Sectors

Healthcare

Portfolio Breakdown

Top 10 holdings (18.0% of the fund)

SymbolCompany% assets
MRNA2.36%
TWST1.98%
NTRA1.90%
HALOZYMETHER1.75%
BIIB1.70%
AMGN1.69%
UTHR1.68%
ABBV1.66%
GILD1.63%
SPYRETHERAPE1.63%

Sector breakdown

  • Health Care100.0%

Holdings from the issuer's published portfolio as at 31 October 2026. Breakdowns are based on the largest 157 positions, covering 100% of the fund. Compare CURE's holdings with other ETFs →

Best-endeavours estimate. Built from each issuer's published holdings, which may be weeks or months old, may cover only part of a fund (some publish only their top 10) and are matched by company name. Figures may be incomplete or inaccurate. Check the issuer's website and PDS before relying on them. General information only.

Similar ETFs

CodeNameSame holdingsMERAUM1Y3Y p.a.5Y p.a.
IVViShares S&P 500 ETF
2%
0.04%$14.9bn+10.1%+19.2%+13.4%
IHVViShares S&P 500 (AUD Hedged) ETF Currency hedged
2%
0.10%$4.3bn+15.4%+21.0%+10.9%
QUSBetashares S&P 500 Equal Weight ETF
2%
0.29%$1.4bn+6.6%+12.0%+7.9%
WXOZState Street SPDR S&P World ex Australia Carbon Aware ETF
2%
0.07%$858m+7.6%+16.9%+9.3%
IJRiShares S&P Small-Cap ETF
1%
0.07%$827m+10.6%+11.5%+5.9%
IJHiShares S&P Midcap ETF
3%
0.07%$485m+6.4%+11.4%+7.8%

Same holdings is the share of CURE's money in companies the other ETF also holds, weighted by size. Most similar first, then ETFs in the same category. See every ETF like CURE →

CURE vs its closest alternatives

What actually differs between CURE and the ETFs most like it. Data to 30 Sep 2026.

IVV iShares S&P 500 ETF

  • They share 2% of their holdings: mostly different companies.
  • IVV is cheaper (0.04% vs 0.45%), worth about $28,398 on $100,000 over 20 years.
  • Over 3 years, a year: CURE +25.7%, IVV +19.2% (CURE ahead by 6.5 percentage points).
  • IVV is much larger ($14.9bn vs $50m), which usually means tighter trading spreads.

Compare CURE and IVV side by side →

IHVV iShares S&P 500 (AUD Hedged) ETF

  • They share 2% of their holdings: mostly different companies.
  • IHVV is cheaper (0.10% vs 0.45%), worth about $24,111 on $100,000 over 20 years.
  • Over 3 years, a year: CURE +25.7%, IHVV +21.0% (CURE ahead by 4.7 percentage points).
  • IHVV is much larger ($4.3bn vs $50m), which usually means tighter trading spreads.
  • Different structure: CURE is a standard fund, IHVV is currency hedged.

Compare CURE and IHVV side by side →

QUS Betashares S&P 500 Equal Weight ETF

  • They share 2% of their holdings: mostly different companies.
  • QUS is cheaper (0.29% vs 0.45%), worth about $10,836 on $100,000 over 20 years.
  • Over 3 years, a year: CURE +25.7%, QUS +12.0% (CURE ahead by 13.6 percentage points).
  • QUS is much larger ($1.4bn vs $50m), which usually means tighter trading spreads.

Compare CURE and QUS side by side →

General information only. Past performance is not a reliable indicator of future performance.

Related Reads

CURE FAQs

What is the fee for CURE?

CURE charges a management fee (MER) of 0.45% a year, according to the TMX Australia monthly funds report as at 30 September 2026.

How big is CURE?

CURE had $50m in funds under management as at 30 September 2026.

How has CURE performed?

CURE returned +50.9% over the year to 30 September 2026 (total return, including distributions). Over three years it returned +25.7% a year. Past performance is not a reliable indicator of future performance.

Who manages CURE?

CURE is managed by Global X and has been listed since November 2018.

Is CURE franked?

Generally no. CURE invests outside Australia, so its distributions carry little or no franking credits. Franking comes from Australian companies that have paid tax here.

What does CURE hold?

CURE's largest holdings are Moderna Inc (2.4%), Twist Bioscience Corp (2.0%), Natera Inc (1.9%), Halozyme Therape (1.8%), Biogen Inc (1.7%). It holds about 157 investments in total. Holdings as at 31 October 2026.

Is CURE currency hedged?

No, CURE is unhedged. Its returns move with the Australian dollar: a falling dollar adds to returns and a rising dollar reduces them.

Disclaimer

This review is general information only and does not take into account your objectives, financial situation or needs. Consider the Global X product disclosure statement (PDS) and target market determination (TMD) before investing. Past performance is not a reliable indicator of future performance.